1-4 of 4
Daelynn R Buelow
Close
Sort by
Journal Articles

High-Dimensional Analysis Identifies Mechanisms of Gilteritinib Resistance in FLT3 -Mutated AML

Daelynn R Buelow, Bhavana Bhatnagar, Jae Yoon Jeon, Megan Zavorka Thomas, Eric Eisenmann, Jack Stromatt, Shelley Orwick, Navjot Pabla, James S. Blachly, Sharyn Baker, Bradley W Blaser
Journal: Blood
Blood (2021) 138 (Supplement 1): 207.
https://doi.org/10.1182/blood-2021-148569
Published: 2021
Journal Articles

TP-0903, a Novel Axl Inhibitor with Activity in Drug Resistant FLT3-ITD+ AML through a Mechanism That Includes FLT3 Inhibition

Jae Yoon Jeon, PharmD, Il-Kyoo Park, PhD, Daelynn R Buelow, PhD, Clifford Whatcott, PhD, Steven L. Warner, PhD, William Blum, MD, Sharyn Baker, PharmD
Journal: Blood
Blood (2017) 130 (Supplement 1): 2522.
https://doi.org/10.1182/blood.V130.Suppl_1.2522.2522
Published: 2017
Journal Articles

Pilot Study of Combined Type I FLT3 Tyrosine Kinase Inhibitor, Crenolanib with Sorafenib in Pediatric Patients with Relapsed/Refractory FLT3+Ve AML

Hiroto Inaba, MD PhD, John C Panetta, PhD, Daelynn R Buelow, PhD, Raul C. Ribeiro, MD, John R. Eckardt, MD, Sharyn D Baker, PharmD, PhD
Journal: Blood
Blood (2016) 128 (22): 3937.
https://doi.org/10.1182/blood.V128.22.3937.3937
Published: 2016
Journal Articles

Genomic Profiling Identifies Novel Mutations and Fusion Genes in Newly Diagnosed and Relapsed Pediatric FLT3-ITD-Positive AML

Daelynn R Buelow, PhD, Stanley Pounds, PhD, Yong-Dong Wang, Lei Shi, PhD, Yongjin Li, PhD, David Finkelstein, Sheila A Shurtleff, PhD, Geoffrey A. Neale, PhD, Hiroto Inaba, MD PhD, Raul C. Ribeiro, MD, Dominique Garrison, Shelley Orwick, BS, James S. Blachly, MD, John C. Byrd, MD, Karl Kroll, Tanja A. Gruber, MD PhD, Jeffrey E Rubnitz, MD PhD, Sharyn D Baker, PharmD, PhD
Journal: Blood
Blood (2016) 128 (22): 2838.
https://doi.org/10.1182/blood.V128.22.2838.2838
Published: 2016